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 Abstract 
 Background: From around the year 2000, Northern Europe experienced a rise in impetigo caused by Staphylococcus aureus 
resistant to fusidic acid. A single clone of S. aureus was found to be the bacterial pathogen involved in the impetigo outbreak 
in Norway, Sweden, the UK and Ireland, termed  ‘ the epidemic European fusidic acid-resistant impetigo clone ’ (EEFIC). 
We have followed the incidence of impetigo during the years 2001 – 2012 based on all patients in general practice in the 
island community of Austevoll, Western Norway. We previously reported a marked decline of impetigo incidence in Austevoll, 
from 0.0260 cases per person-year in 2002 to 0.0038 in 2009. This article explores indications of an end to the impetigo 
epidemic caused by the EEFIC clone.  Methods: All four general practitioners (GPs) in the community (mean 
population    4400) were asked to diagnose impetigo in a uniform way and to take bacterial specimens from all impetigo 
cases. Phenotypic characteristics of specimen bacteria were determined for the whole period and molecular analyses were 
performed on isolates in the period 2008 – 2012.  Results: We observed a further decline in incidence of impetigo in Austevoll 
in the study period. The proportion of fusidic acid-resistant S. aureus isolates decreased during the period 2002 – 2012, with 
a mean of 80% in the epidemic years of 2002 – 2004, 55% in 2005 – 2009, and 6% in 2010 – 2012. In total, 44 S. aureus 
isolates from impetigo were subject to molecular analyses in the period 2008 – 2012, and 11 were found to be related to the 
EEFIC. All EEFIC isolates were found in 2008 – 2009, with no new isolates in 2010 – 2012.  Conclusion: There is an apparent 
end to the impetigo epidemic related to the EEFIC in this population in Western Norway. 
 Keywords:  Impetigo ,  population-based ,  Staphylococcus aureus ,  fusidic acid resistance ,  clone 
 Introduction 
 From around the year 2000, Northern Europe 
experienced a rise in superfi cial skin infections, 
most often diagnosed as impetigo. In many cases the 
infections were caused by Staphylococcus aureus 
resistant to fusidic acid [1,2]. In 2003, O ’ Neill and 
collaborators identifi ed a single clone of S. aureus as 
being the bacterial pathogen involved in the impetigo 
outbreak in Norway, Sweden, the UK and Ireland 
[3]. They termed this clone  ‘ the epidemic European 
fusidic acid-resistant impetigo clone ’ (EEFIC), and 
later performed a comprehensive molecular charac-
terization of the clone [4]. 
 Several studies documented the presence of the 
EEFIC being related to elevated numbers of impe-
tigo cases in Norway [1], Sweden [2], the UK and 
Ireland [3]. Later, the presence of the clone was also 
confi rmed in France [5] and the Netherlands [6]. 
 In 2011, we reported data on the incidence and 
bacteriology of impetigo in the Norwegian island 
community of Austevoll during the years 2001 – 2009 
[7]. Phenotypic characteristics of the bacteria were 
determined for the whole period, and in 2008 and 
2009 molecular analyses were performed on selected 
isolates. The prevalence of the EEFIC was much less 
in 2009 than in 2008, indicating an attenuation of 
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the impetigo epidemic caused by the EEFIC. Fur-
ther suggestions of a decrease of the EEFIC came 
from studies from Sweden [8] and Denmark [9], 
showing falling rates of fusidic acid resistance in 
impetigo-related S. aureus isolates in the latter half 
of the fi rst decade after the year 2000. 
 In the current study, we wanted to explore indica-
tions of an end to the impetigo epidemic caused by 
the EEFIC in the community of Austevoll, Norway, 
based on continued data for the years 2010 – 2012. 
 Materials and methods 
 The study was performed during the years 2001 –
 2012 in the island municipality of Austevoll, Western 
Norway. The municipality had a mean population of 
4400 inhabitants during the study period. The con-
nection to the mainland is by boats and ferries only. 
During the study period the mean number of general 
practitioners (GPs) in the municipality was four. The 
GPs share a common Electronic Patient Journal 
(EPJ) system, and they agreed to record all cases of 
impetigo in a uniform way. Impetigo was defi ned as 
a superfi cial skin infection with spontaneous erup-
tion of erosions being covered by honey-coloured 
crusts. The GPs were encouraged to take bacterial 
specimens from all impetigo cases. The bacterial 
specimens were sent to the Department of Microbi-
ology, Haukeland University Hospital, Bergen, Nor-
way. Annual incidence of impetigo was calculated 
and epidemic season was defi ned according to a stan-
dard procedure [10]. 
 In addition, the project leader (S.R.), who was 
one of the community GPs, collected bacterial spec-
imens from cases of other bacterial skin infections, 
for comparison with the impetigo cases. These non-
impetigo specimens were not collected according to 
specifi c criteria. Bacteria in all specimens were 
detected and identifi ed by standard methods. The 
susceptibility of S. aureus to penicillin G, oxacillin, 
erythromycin, fusidic acid and clindamycin was 
determined using disc diffusion tests. From Decem-
ber 2012 antimicrobial susceptibility testing (AST) 
was done according to the EUCAST disc diffusion 
method. Before this, AST was done according to the 
Norwegian Working Group on Antibiotics (NWGA). 
Before the laboratory changed the method for sus-
ceptibility testing, the two methods were compared. 
Regarding susceptibility categorization (sensitive/
intermediate/resistant), the two methods were found 
to be comparable. 
 Molecular epidemiological typing was performed 
on available S. aureus isolates in the period 2008 –
 2012. Both pulsed-fi eld gel electrophoresis (PFGE) 
and staphylococcal protein A typing ( spa -typing) 
were used. Although different, the methods are 
thought to be comparable when it comes to classify-
ing an isolate as belonging to the EEFIC clone or 
not. In this period, 83 impetigo cases were registered, 
77 swabs were taken and S. aureus was isolated in 
52 cases. 
 In the years 2008 – 2009, all available impetigo S. 
aureus isolates ( n    28) were investigated by PFGE. 
Band patterns were compared visually and differ-
ences were evaluated as described by Tenover et  al. 
[11]. Isolates indicated by PFGE to belong to the 
EEFIC ( n    11), and fusidic acid-resistant (FAR) 
isolates not found by PFGE to be related to the 
EEFIC ( n    2), were further analysed by  spa typing, 
which was performed at St Olavs Hospital, Trond-
heim, Norway, as described previously [12]. 
 In the years 2010 – 2012, the PFGE method was 
no longer an available laboratory method. In this 
period, all available impetigo S. aureus isolates 
( n    16) were investigated by  spa typing instead. A 
few impetigo S. aureus isolates (6 of 34 isolates from 
2008 – 2009 and 2 of 18 from 2010 – 2012) were lost 
to further molecular analyses. 
 By PFGE analysis, all 11 non-impetigo S. aureus 
isolates in the years 2008 – 2009 were found not to be 
related to the EEFIC, and were not subjected to fur-
ther  spa typing. Nineteen non-impetigo S. aureus 
isolates from 2010 – 2012 were all sent for  spa typing. 
To be defi ned as EEFIC in the present study, isolates 
had to show  spa typing at least closely related to the 
EEFIC reference strain ( spa type t171) [1,3,4]. 
 Continuous surveillance of the impetigo inci-
dence and FAR S. aureus prevalence has been the 
main focus of the Austevoll impetigo study. We have 
previously documented falling rates of these variables 
since the start of the epidemic in 2002 – 2003 and 
forward up to 2009 [10]. We retrospectively collected 
data on prevalence and bacteriology of impetigo 
cases for the last half of 2001. 
 To investigate a possible end to the EEFIC-
related impetigo epidemic in Austevoll, we here pres-
ent the data for the years 2010 – 2012 as an extension 
of the data from the previous years. For overview, we 
also present some previously published data. 
 Ethics 
 Ethics approval was obtained from the Regional 
Committee for Medical and Health Research Ethics 
of Western Norway, and the study was also approved 
by the Ombudsman for Privacy in Research, Norwe-
gian Social Science Data Services. 
 Results 
 In total, 484 impetigo cases were registered, and bac-
terial specimens were collected from 388 of these 
Sc
an
d 
J I
nf
ec
t D
is 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ite
tsb
ib
lio
te
ke
t i
 B
er
ge
n 
on
 1
2/
29
/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
834 S. R ø rtveit et al. 
cases. Table I shows the annual incidence of impetigo 
for the period 2001 – 2012. After a maximum in 2002, 
there was a marked decline in incidence, and there 
was no epidemic season after 2004 [10]. Altogether, 
bacterial swabs were taken from 80% of the patients, 
and S. aureus was grown in 76% of the cases where 
swabs were taken (Table I). The proportion of FAR 
S. aureus isolates decreased during the period 2002 –
 2009, with a mean of 80% in the epidemic years 
2002 – 2004, 55% in 2005 – 2009 [7]. The decline con-
tinued and reached 6% in 2010 – 2012. These declin-
ing trends are depicted in Figure 1. 
 In total, 44 S. aureus isolates from impetigo were 
subject to molecular analyses, and 11 were found to 
be related to the EEFIC (Table II). Of the 11 EEFIC 
isolates from 2008 – 2009, none showed PFGE iden-
tity with the reference strain collected in 2001, but 
all had closely related PFGE patterns. Eight had 
identical  spa type (t171), while three strains had the 
closely related  spa types of t659 (two isolates) and 
t645 [7]. 
 Of the 33 non-EEFIC S. aureus isolates from 
impetigo, 30 (91%) were susceptible to fusidic acid. 
The EEFIC clone was responsible for 77% (10 of 
13) of impetigo S. aureus isolates with resistance to 
fusidic acid, and 91% (10 of 11) of EEFIC isolates 
were FAR [7]. 
 In 2010 – 2012, no new EEFIC isolates were 
found. The detailed listing of  spa types from both 
impetigo and non-impetigo specimens from this 
period is shown in Table II. Two  spa types were 
involved in both impetigo and non-impetigo skin 
infections; t084 were found in seven impetigo infec-
tions and in three non-impetigo infections, and t127 
were found in one impetigo infection and in four 
non-impetigo infections.  spa type t127 was respon-
sible for all cases of FAR during the years 2010 –
 2012, both the one impetigo case and three 
non-impetigo cases. One isolate with  spa type t127 
was susceptible to fusidic acid. 
 Of 11 S. aureus isolates from skin infections other 
than impetigo during the years 2008 – 2009 analysed 
by susceptibility testing and PFGE, all turned out to 
be fusidic acid susceptible, and none were related to 
the EEFIC [7]. In the years 2010 – 2012, 3 of the 19 
S. aureus isolates from non-impetigo skin infections 
were FAR, but none were related to the EEFIC. 
0
20
40
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80
100
120
140
Impetigo cases
S. aureus
Fusidic acid resistance
 Figure 1. Number of impetigo cases, S. aureus isolates in impetigo 
and fusidic acid-resistance in S. aureus in impetigo, in Austevoll 
2002 – 2012. 
 Table I. Yearly incidence rates and microbial characteristics of impetigo in the total population of Austevoll, Western Norway ( n    4400) a . 
Impetigo 
cases
 n 
Incidence
Per 1000 
person-years
Swabs taken Growth of 
S. aureus
 n (%)
Fus res b 
 n (%)
PFGE 
performed
 spa typing 
performed
EEFIC isolates Non-EEFIC isolates
Fus res
 n (%)
Fus sens
 n (%)
Fus res
 n (%)
Fus sens
 n (% ) Year  n (%)
2001 c 20 0.0091 10 (50) 9 (90) 6 (67)
2002 d 115 0.0260 90 (78) 75 (83) 65 (87)
2003 d 85 0.0192 63 (74) 47 (74) 33 (70)
2004 d 72 0.0163 53 (74) 46 (87) 37 (80)
2005 42 0.0095 39 (93) 24 (62) 11 (46)
2006 42 0.0100 38 (90) 27 (71) 16 (59)
2007 25 0.0057 18 (72) 16 (89) 13 (81)
2008 35 0.0079 35 (100) 25 (71) 11 (44) 21 9 8 (89) 1 (11) 0 (0) 12 (100)
2009 17 0.0038 15 (88) 9 (60) 5 (56) 7 4 2 (100) 0 (0) 2 (40) 3 (60)
2010 11 0.0025 10 (91) 7 (70) 1 (14) 6 0 (0) 0 (0) 1 (17) 5 (83)
2011 7 0.0016 7 (100) 4 (57) 0 (0) 4 0 (0) 0 (0) 0 (0) 4 (100)
2012 13 0.0029 10 (77) 7 (70) 0 (0) 6 0 (0) 0 (0) 0 (0) 6 (100)
 EEFIC, epidemic European fusidic acid-resistant impetigo clone; Fus res, resistance to fusidic acid; Fus sens, sensitive to fusidic acid; 
PFGE, pulsed-fi eld gel electrophoresis. 
 a Data from the period 2001 – 2009 have been published previously [7,10]. 
 b Proportion of swabs with fusidic acid resistance per number of swabs with S. aureus isolates. 
 c In 2001 impetigo was registered for the last half year. 
 d Years of epidemic impetigo outbreak [10]. 
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 Discussion 
 In the present study there was a parallel decline in 
impetigo rate and the proportion of FAR S. aureus 
isolated from impetigo during the years 2002 – 2012. 
No impetigo isolates were FAR in 2011 and 2012. 
For the years 2008 – 2012 the vast majority of fusidic 
acid resistance in S. aureus in impetigo was caused 
by the EEFIC, making it reasonable to argue that the 
great predominance of fusidic acid resistance during 
the years 2002 – 2007 was also driven by the EEFIC. 
 The data from the present study suggest that, as 
far as the community of Austevoll is concerned, the 
epidemic related to the EEFIC has come to an end. 
 Whether this conclusion is generalizable to all 
of Norway, and to all of Northern Europe, is an 
important question. The EPISA study of antimi-
crobial susceptibility of S. aureus-related skin and 
soft tissue infections in general practice in France, 
the UK and Ireland during 2003 – 2004 found a 
high proportion of EEFIC identifi ed in impetigo 
[5]. In 2012, Dutch researchers investigated the 
prevalence of the EEFIC in general practice patients 
with skin or soft tissue infections during 2007 and 
2008 [6], and they identifi ed EEFIC in a little over 
30% of S. aureus isolates from skin lesions. How-
ever, these two studies do not give data about time 
trends of the EEFIC prevalence. 
 A Swedish follow-up study from the years 1993 –
 2004 investigating the prevalence of S. aureus isolates 
being resistant to fusidic acid (FAR) in selected 
nationwide microbiological laboratories, found the 
proportion of FAR for superfi cial skin and soft tissue 
infections in children to decline from a maximum of 
about 47% in 2002 to 35% in 2004 [13]. Another 
 Table II. Susceptibility testing,  spa typing and relatedness to EEFIC in 44 impetigo and 33 non-impetigo 
Staphylococcus aureus isolates from the years 2008 – 2012. 
Year Isolate no.
Fusidic acid 
susceptibility
PFGE-relatedness 
to EEFIC  Spa type
 spa -relatedness 
 to EEFIC
Impetigo isolates
2008 – 09
1 – 8 R CR t171 ID
9 S CR t645 CR
10 – 11 R CR t659 CR
12 – 13 R NR t008 NR
14 – 28 S NR NA NA
2010 – 12
29 – 35 S NA t084 NR
36 S NA t505 NR
37 S NA t726 NR
38 S NA t330 NR
39 R NA t127 NR
40 S NA t160 NR
41 S NA t015 NR
42 S NA t334 NR
43 S NA t094 NR
44 S NA t085 NR
Non-impetigo isolates
2008 – 09
45 – 55 S NR NA NA
2010 – 12
56 – 58 S NA t084 NR
59-61 R NA t127 NR 
62 S NA t127 NR
63 S NA t085 NR
64 S NA t026 NR
65 S NA t12271 NR
66 S NA t116 NR
67 S NA t091 NR
68 S NA t279 NR
69 S NA t216 NR
70 S NA t2119 NR
71 S NA t065 NR
72 S NA t136 NR
73 S NA t2133 NR
74 S NA t002 NR
 CR, closely related; ID, identical; NA, not applicable; NR, not related. 
Sc
an
d 
J I
nf
ec
t D
is 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ite
tsb
ib
lio
te
ke
t i
 B
er
ge
n 
on
 1
2/
29
/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
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Swedish study of patients attending a dermatological 
outpatient clinic for impetigo and infected atopic der-
matitis in the years 2004 – 2008 showed that the pro-
portion of FAR in impetigo and infected atopic 
dermatitis caused by S. aureus was diminishing simul-
taneously, with the proportion of FAR in impetigo 
decreasing from 33% to 24% over the years [8]. 
 In 2011, a population-based study from Northern 
Denmark recorded bacterial data from skin and 
mucosal membranes of patients with skin infections 
for the time period of 1997 – 2008 [9]. They found 
that the prevalence of S. aureus isolated in impetigo 
had a marked rise to a maximum in 2002, with a 
gradual decline thereafter. The proportion of the 
impetigo S. aureus isolates that were FAR was almost 
50% during the years 2003 – 2006, and diminished 
after that. In the 2012 report of the Norwegian Anti-
biotic Resistance Surveillance system [14], national 
data suggested the fusidic acid resistance to S. aureus 
in wound isolates to be reduced from a maximum of 
25% in 2004 to a stable level of about 10% from the 
year 2008 on. A study from the UK for the years 
1995 – 2010, which was based on a large primary care 
diagnosis database, showed national impetigo inci-
dence to double from 1995 to 2001, and to regress 
to a little below the baseline of 1995 by 2010 [15]. 
However, neither of these studies provided molecular 
data. 
 It is likely that these identifi able trends of dimin-
ishing prevalence of S. aureus fusidic acid resistance 
in Sweden, Denmark and Norway, and of impetigo 
in the UK, indicate a signifi cant attenuation of the 
presence of EEFIC in these countries. 
 More epidemiological studies of superfi cial skin 
infections from different parts of Northern and Central 
Europe, involving application of molecular analyses of 
the bacteria, are needed to confi rm this conclusion. 
However, we fi nd the results from the current study 
suffi cient to suggest that the impetigo epidemic related 
to the EEFIC is most likely near its end. 
 Another question is to what degree the EEFIC 
has specifi cally been the cause of impetigo and not 
of other skin infections like skin abscesses, parony-
chiae and other infections of fi ngers and toes, super-
infection of atopic dermatitis, folliculitis, furunculosis 
and cellulitis. 
 When O ’ Neill et  al fi rst described the EEFIC [4], 
they found that the clone possesses genes previously 
known to be linked to impetigo, like exfoliative toxins 
A and B and EDIN-C. In a previous article analysing 
our material from the years 2001 – 2005, we showed 
an inverse relationship between the proportion of 
FAR in impetigo and in other superfi cial skin infec-
tions, as the proportion of FAR in impetigo at the 
time was 76% and for other superfi cial skin infec-
tions it was 18% [10]. 
 Our recent data from 2010 – 2012 show that a 
diversity of  spa types cause both impetigo and non-
impetigo infections. The most common  spa type 
found in impetigo is also frequently identifi ed in non-
impetigo skin infections, indicating that the strains 
of S. aureus that are most prevalent at present do not 
possess the same specifi city for impetigo as the 
EEFIC did. 
 Based on our material, it seems reasonable to 
maintain that the EEFIC has been specifi cally 
inclined to be associated with impetigo, but not 
with other superfi cial skin infections. On the con-
trary, other studies such as the EPISA study [5] and 
the study by Rijnders et  al. from the Netherlands 
[6], found the EEFIC in other types of skin infec-
tions as well as in impetigo. However, these studies 
do not seem to be based on accurate clinical data. 
Possibly, their results may have been subject to mix-
ing of cases of impetigo and other skin infections, 
thus not being able to identify the high degree of 
impetigo specifi city in EEFIC. The present study is 
based on cases with strict clinical diagnosis as an 
inclusion criterion. 
 The strengths of our study are the exact number 
of the total population under study, the clinical defi -
nition of the cases to be included as impetigo patients, 
the reliable identifi cation of all impetigo patients and 
the uniform registration over a long timespan. Weak-
nesses of the study are that we do not have molecu-
lar analyses for the fi rst 6 years, that the molecular 
methods were not uniformly performed in the peri-
ods 2008 – 2009 and 2010 – 2012, and that the num-
ber of patients in recent years has been small, thus 
reducing the generalizability of the conclusions. 
 The steady decline over the years of S. aureus 
fusidic acid resistance in impetigo and the consistent 
absence of EEFIC during the last 3 years are strong 
indications of the extinction of this epidemic in our 
community. 
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